Showing results (91-100 of 178) with videos related to

Sort By:
Pageof 18
Circulation. Cardiovascular Interventions|December 25, 2009
Poor 1-year outcomes after percutaneous coronary interventions in systemic lupus erythematosus: report from the National Heart, Lung, and Blood Institute Dynamic RegistryKathleen Maksimowicz-McKinnon, Faith Selzer, Susan Manzi, et al.
Annals of the Rheumatic Diseases|May 17, 2022
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trialsIan N Bruce, Richard A Furie, Eric F Morand, et al.
Annals of the Rheumatic Diseases|March 26, 2022
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trialsEdward M Vital, Joan T Merrill, Eric F Morand, et al.
The Journal of Rheumatology|May 23, 2007
Association study of Toll-like receptor 5 (TLR5) and Toll-like receptor 9 (TLR9) polymorphisms in systemic lupus erythematosusF Yesim K Demirci, Susan Manzi, Rosalind Ramsey-Goldman, et al.
The American Journal of Cardiology|September 9, 2008
C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritisAmy H Kao, Mary Chester M Wasko, Shanthi Krishnaswami, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 30, 2025
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP-SC StudySusan Manzi, Ian N Bruce, Eric F Morand, et al.
International Journal of Experimental Pathology|June 27, 2002
Evidence for a perforin-mediated mechanism controlling cardiac inflammation in Trypanosoma cruzi infectionAndrea Henriques-Pons, Gabriel M Oliveira, Mauricio M Paiva, et al.
The Lancet. Rheumatology|January 17, 2024
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialRichard A Furie, Eric F Morand, Ian N Bruce, et al.
The Journal of Rheumatology|May 23, 2002
The rate and pattern of organ damage in late onset systemic lupus erythematosusPeter Maddison, Vernon Farewell, David Isenberg, et al.
Annals of the Rheumatic Diseases|May 3, 2012
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsSusan Manzi, Jorge Sánchez-Guerrero, Joan T Merrill, et al.
Pageof 18